Pacific Biosciences of California, Inc.

DB:P09 Stock Report

Market Cap: €480.3m

Pacific Biosciences of California Valuation

Is P09 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of P09 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: P09 (€1.77) is trading below our estimate of fair value (€12.87)

Significantly Below Fair Value: P09 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for P09?

Key metric: As P09 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for P09. This is calculated by dividing P09's market cap by their current revenue.
What is P09's PS Ratio?
PS Ratio2.8x
SalesUS$173.15m
Market CapUS$492.95m

Price to Sales Ratio vs Peers

How does P09's PS Ratio compare to its peers?

The above table shows the PS ratio for P09 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
EVT Evotec
1.9x12.1%€1.5b
GXI Gerresheimer
1.2x9.8%€2.4b
1SXP SCHOTT Pharma KGaA
3.9x10.4%€3.7b
SRT3 Sartorius
4.4x8.8%€13.4b
P09 Pacific Biosciences of California
2.8x18.8%€493.0m

Price-To-Sales vs Peers: P09 is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does P09's PS Ratio compare vs other companies in the European Life Sciences Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
P09 2.8xIndustry Avg. 4.4xNo. of Companies6PS03.26.49.612.816+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: P09 is good value based on its Price-To-Sales Ratio (2.8x) compared to the European Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is P09's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

P09 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.8x
Fair PS Ratio3.4x

Price-To-Sales vs Fair Ratio: P09 is good value based on its Price-To-Sales Ratio (2.8x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst P09 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.77
€2.88
+62.6%
37.1%€5.72€1.91n/a12
Dec ’25€1.79
€2.88
+61.0%
37.1%€5.72€1.91n/a12
Nov ’25€1.95
€2.85
+46.3%
44.6%€6.45€1.84n/a11
Oct ’25€1.62
€2.70
+66.6%
47.1%€6.30€1.80n/a11
Sep ’25€1.23
€2.70
+119.8%
47.1%€6.30€1.80n/a11
Aug ’25€1.80
€3.90
+116.6%
71.8%€11.93€1.84n/a12
Jul ’25€1.18
€3.90
+230.5%
71.8%€11.93€1.84n/a12
Jun ’25€1.64
€3.96
+141.2%
74.6%€12.05€1.85n/a11
May ’25€1.55
€5.47
+252.5%
60.5%€12.21€2.35n/a11
Apr ’25€3.37
€9.31
+176.4%
22.9%€13.90€6.02n/a11
Mar ’25€5.02
€9.73
+94.0%
23.7%€13.84€6.00n/a12
Feb ’25€5.92
€11.22
+89.7%
26.9%€17.46€7.35n/a12
Jan ’25n/a
€10.77
0%
27.9%€17.17€7.23€1.7712
Dec ’24€7.66
€11.61
+51.6%
31.5%€18.34€7.33€1.7912
Nov ’24€5.76
€12.28
+113.4%
29.3%€18.90€7.56€1.9512
Oct ’24€7.83
€13.97
+78.4%
20.9%€18.94€8.52€1.6212
Sep ’24€10.29
€14.13
+37.3%
15.1%€18.17€11.81€1.2311
Aug ’24n/a
€13.50
0%
16.9%€18.33€11.00€1.8011
Jul ’24€11.98
€13.50
+12.7%
16.9%€18.33€11.00€1.1811
Jun ’24€11.14
€12.35
+10.8%
10.5%€15.48€10.93€1.649
May ’24n/a
€11.41
0%
13.4%€13.83€9.22€1.558
Apr ’24€8.80
€11.41
+29.7%
13.4%€13.83€9.22€3.378
Mar ’24€8.22
€11.44
+39.1%
11.2%€13.20€9.43€5.028
Feb ’24€10.10
€11.54
+14.3%
10.3%€13.30€9.50€5.927
Jan ’24€7.74
€11.90
+53.7%
12.1%€13.51€9.65n/a6

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 08:59
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacific Biosciences of California, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Kyle MiksonCanaccord Genuity
Bryan BrokmeierCantor Fitzgerald & Co.